TALL 104

Drug Profile

TALL 104

Alternative Names: ABIO-05/01; ABIO-0501; TALL-104

Latest Information Update: 29 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wistar Institute
  • Developer Abiogen Pharma; Galileo Research; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ovarian cancer; Peritoneal cancer
  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 29 Jul 2015 No recent reports on development identified - Phase-I/II for Peritoneal cancer in Italy (IV & Intraperitoneal)
  • 13 Feb 2014 No development reported - Phase-II for Ovarian cancer in Italy (Parenteral)
  • 01 May 2013 Abiogen Pharma terminates phase I trial in Chronic myeloid leukaemia (combination therapy, second-line therapy or greater) in USA (NCT00415909)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top